<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session</th>
<th>proposed chair person</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mar. 1st</td>
<td>18:00-18:10</td>
<td>Opening remark</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>18:10-19:30</td>
<td>Keynote Lecture</td>
<td>Dr. Lowe, Dr. Sakamoto</td>
<td>Molecular pathology of multistage hepatocarcinogenesis</td>
<td>Dr. Michiie Sakamoto (Keio Univ.)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Integrated Approaches To Cancer Gene Discovery Using Mouse Models And</td>
<td>Dr. Scott Lowe (Cold Spring Harbor Lab)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RNAi</td>
<td></td>
</tr>
<tr>
<td></td>
<td>20:00</td>
<td>Welcome Party</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8:00-10:00</td>
<td>1. Pathogenic agents and Molecular epidemiology</td>
<td>Dr. Ploss, Dr. Shimotoho</td>
<td>Novel targets for anti HCV drugs preventing infectious virus particle</td>
<td>Dr. Makoto Hijikata (Kyoto Univ.)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>production</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Analysis of Hepatitis C virus infection and pathogenesis in small</td>
<td>Dr. Alexander Ploss (The Rockefeller Univ. NY)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>animal models</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Direct cytopathic effects by hepatitis B virus</td>
<td>Dr. Yasuhito Tanaka (Nagoya City Univ.)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Efficacy of peg-IFN/Ribavirin combination therapy in hepatitis C</td>
<td>Dr. Naoki Hiramatsu (Osaka Univ.)</td>
</tr>
<tr>
<td></td>
<td>10:00-10:20</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10:20-11:50</td>
<td>2. Preneoplastic liver injury</td>
<td>Dr. Friedman, Dr. Kaneko</td>
<td>Gene expression profiles of chronic viral hepatitis</td>
<td>Dr. Shuichi Kaneko (Kanazawa Univ.)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Inflammation in the pathogenesis of genetic alteration leading to</td>
<td>Dr. Hiroyuki Marusawa (Kyoto Univ.)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>liver carcinogenesis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Senescence Surveillance in Hepatocellular Carcinoma</td>
<td>Dr. Lars Zender (Hannover Medical School, Germany)</td>
</tr>
<tr>
<td></td>
<td>11:50-12:50</td>
<td>Lunch &amp; poster view</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>12:50-14:20</td>
<td>Poster presentation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>14:20-15:20</td>
<td>2. Preneoplastic liver injury</td>
<td>Dr. Friedman, Dr. Kaneko</td>
<td>Permissive effects of fibrosis and the microenvironment on HCC</td>
<td>Dr. Scott L. Friedman (Mount Sinai School of Medicine, NY)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>development</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hepatic phosphorylated smads signaling between tumor suppression and</td>
<td>Dr. Koichi Matsuzaki (Kansai medical Univ.)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>hepatocarcinogenesis in chronic hepatitis C</td>
<td></td>
</tr>
<tr>
<td></td>
<td>15:20-15:40</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>15:40-17:10</td>
<td>3. Molecular carcinogenesis</td>
<td>Dr. Harris, Dr. Aburatani</td>
<td>p53, microRNAs and senescence in human carcinogenesis</td>
<td>Dr. Curtis C. Harris (National Cancer Institute, MD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hepatocarcinogenesis in HCV infection</td>
<td>Dr. Kazuiko Kolke (Tokyo Univ.)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DNA methylation alterations during multistage hepatocarcinogenesis</td>
<td>Dr. Yae Kanai (National Cancer Center)</td>
</tr>
<tr>
<td></td>
<td>17:30-19:00</td>
<td>Meet-the Expert Evening (all participants)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>19:30-21:30</td>
<td>Banquet</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mar. 2nd</td>
<td>8:00-9:00</td>
<td>3. Molecular carcinogenesis</td>
<td>Dr. Harris, Dr. Aburatani</td>
<td>Decoding of virus-associated liver cancer genome</td>
<td>Dr. Tatsuhito Shibata (National Cancer Center)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Integrated genomic analysis of liver cancer</td>
<td>Dr. Hiroyuki Aburatani (Tokyo Univ.)</td>
</tr>
<tr>
<td></td>
<td>9:00-10:00</td>
<td>4. Molecular diagnosis</td>
<td>Dr. Villanueva, Dr. Sakamoto</td>
<td>HHM (Human homologue of Mait) : an important regulator to control</td>
<td>Dr. Shuji Terai (Yamaguchi Univ.)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>hepatocarcinogenesis and liver fibrosis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Molecular pathogenesis of hepatocellular carcinoma: preliminary steps</td>
<td>Dr. Augusto Villanueva (BCLC, Spain)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>in personalized medicine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10:00-10:20</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10:20-10:50</td>
<td>4. Molecular diagnosis</td>
<td>Dr. Villanueva, Dr. Sakamoto</td>
<td>Development of highly sensitive assay of serum hTERT mRNA for</td>
<td>Dr. Goshi Shiota (Tottori Univ.)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>diagnosis of hepatocellular carcinoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10:50-11:50</td>
<td>5. Metastasis and stem cells</td>
<td>Dr. Gouon-Evans, Dr. S. Tanaka</td>
<td>Regulation of liver cancer stem cells by polycomb group proteins</td>
<td>Dr. Tetsuhiro Chiba (Chiba Univ.)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>The endothelial cell niche controls the development of hepatic</td>
<td>Dr. Valerie Gouon-Evans (Mount Sinai School of Medicine, NY)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>progenitors</td>
<td></td>
</tr>
<tr>
<td></td>
<td>11:50-12:50</td>
<td>Lunch &amp; Poster view</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>12:50-13:20</td>
<td>6. Metastasis and stem cells</td>
<td>Dr. Gouon-Evans, Dr. S. Tanaka</td>
<td>Microenvironment and stemness potentials in hepatocellular</td>
<td>Dr. Shinji Tanaka (Tokyo Medical and Dental Univ.)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>carcinoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>13:20-14:20</td>
<td>6. Molecular targeted therapy</td>
<td>Dr. Wang, Dr. Ohdan</td>
<td>Targeting cancer stem cells defined by HCC subtypes</td>
<td>Dr. Taro Yamashita (Kanazawa Univ.)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Integrative analysis of liver cancer omic data: linking genomics and</td>
<td>Dr. Xin Wei Wang (National Cancer Institute, MD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>phenomics to identify novel molecular targets</td>
<td></td>
</tr>
<tr>
<td></td>
<td>14:20-14:40</td>
<td>Coffee break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>14:40-15:40</td>
<td>6. Molecular targeted therapy</td>
<td>Dr. Wang, Dr. Ohdan</td>
<td>Development of ALN-VSP: an RNAi therapeutic for solid tumors</td>
<td>Dr. David Bumcrot (Alnylam Pharmaceuticals Inc, MA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Adoptive immunotherapy for inducing anti-HCC and anti-HCV activity</td>
<td>Dr. Hideki Ohdan (Hiroshima Univ.)</td>
</tr>
<tr>
<td></td>
<td>15:40-15:50</td>
<td>Closing remark</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>